tiprankstipranks
Medicinova (MNOV)
NASDAQ:MNOV

Medicinova (MNOV) Stock Price & Analysis

280 Followers

MNOV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.26 - $2.66
Previous Close$1.36
Volume264.30K
Average Volume (3M)56.94K
Market Cap
$67.68M
Enterprise Value$16.90M
Total Cash (Recent Filing)$51.00M
Total Debt (Recent Filing)$215.93K
Price to Earnings (P/E)-7.8
Beta0.43
Apr 26, 2023
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding49,046,246
10 Day Avg. Volume40,335
30 Day Avg. Volume56,942
Standard Deviation0.12
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.90
Enterprise Value/Gross Profit16.90
Enterprise Value/Ebitda-1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

71.66%2.56%4.12%21.67%
71.66%
Insiders
4.12% Other Institutional Investors
21.67% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

MNOV FAQ

What was Medicinova’s price range in the past 12 months?
Medicinova lowest stock price was $1.26 and its highest was $2.66 in the past 12 months.
    What is Medicinova’s market cap?
    Currently, no data Available
    When is Medicinova’s upcoming earnings report date?
    Medicinova’s upcoming earnings report date is Apr 26, 2023 which is 337 days ago.
      How were Medicinova’s earnings last quarter?
      Medicinova released its earnings results on Jul 27, 2022. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.063.
        Is Medicinova overvalued?
        According to Wall Street analysts Medicinova’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Medicinova pay dividends?
          Medicinova does not currently pay dividends.
          What is Medicinova’s EPS estimate?
          Medicinova’s EPS estimate is -$0.07.
            How many shares outstanding does Medicinova have?
            Medicinova has 49,046,246 shares outstanding.
              What happened to Medicinova’s price movement after its last earnings report?
              Medicinova reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went down -1.835%.
                Which hedge fund is a major shareholder of Medicinova?
                Among the largest hedge funds holding Medicinova’s share is Caxton Associates LP. It holds Medicinova’s shares valued at N/A.
                  ---

                  Medicinova Stock Smart Score

                  Company Description

                  Medicinova

                  MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Gilead Sciences
                  Amgen
                  Regeneron
                  Biogen
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis